# 25-NB

The 25-NB (25x-NBx) series, or NBOMe series, also known as the N-benzylphenethylamines, is a family of serotonergic psychedelics. They are substituted phenethylamines and were derived from the 2C family. The most commonly encountered NBOMe drugs are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe.
The NBOMe drugs act as selective agonists of the serotonin 5-HT$_2$ receptors. The 25-NB family is unique relative to other classes of psychedelics in that they are, generally speaking, extremely potent and quite selective for the 5-HT$_2$ receptors.
Use of NBOMe series drugs has caused many deaths and hospitalisations since the drugs popularisation in the 2010s. This is primarily due to their high potency, unpredictable pharmacokinetics, and sellers passing off the compounds in the series as LSD.

## Use

Doses and durations of 25-NB or NBOMe drugs :
| Compound | Chemical name | Dosage | Duration |
| 25B-NBOMe | N-(2-Methoxybenzyl)-4-bromo-2,5-dimethoxyphenethylamine | 50–700+ μg | 8–12 hours |
| 25C-NBOMe | N-(2-Methoxybenzyl)-4-chloro-2,5-dimethoxyphenethylamine | 50–1,250+ μg | 3–10 hours |
| 25E-NBOMe | N-(2-Methoxybenzyl)-4-ethyl-2,5-dimethoxyphenethylamine | 50–800 μg | 5–10 hours |
| 25I-NBOMe | N-(2-Methoxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine | 50–1,200 μg | 4–10 hours |
| 25N-NBOMe | N-(2-Methoxybenzyl)-4-nitro-2,5-dimethoxyphenethylamine | 100–1,300+ μg | 5–10 hours |
| Notes: The route of administration is sublingual, insufflation, and/or buccal. They may also be smoked. NBOMe drugs have very low oral bioavailability. ||||

## Pharmacology
### Pharmacodynamics
#### Actions

The NBOMe drugs are highly potent and selective agonists of the serotonin 5-HT$_2$ receptors, including of the 5-HT$_{2A}$, 5-HT$_{2B}$, and 5-HT$_{2C}$ receptors. However, they are much less potent and efficacious at the serotonin 5-HT$_{2B}$ receptor compared to the serotonin 5-HT$_{2A}$ and 5-HT$_{2C}$ receptors. The drugs are highly selective for the serotonin 5-HT$_2$ receptors over other serotonin receptors and over a variety of other biological targets. They are likewise inactive as monoamine reuptake inhibitors and releasing agents. Many of the NBOMe drugs are partial agonists of the rat and mouse trace amine-associated receptor 1 (TAAR1), but they are inactive as agonists of the human TAAR1.

#### Effects

In accordance with their psychedelic effects, NBOMe drugs induce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. They have also been found to produce hyperlocomotion at low doses and hypolocomotion at high doses in rodents.
Unlike most other serotonergic psychedelics, the NBOMe drugs 25B-NBOMe and 25N-NBOMe have been found to produce reinforcing effects in rodents, and hence may have misuse potential. Relatedly, 25B-NBOMe robustly increased dopamine levels in the nucleus accumbens similarly to methamphetamine. The reinforcing effects of 25B-NBOMe were not blocked by serotonin 5-HT$_{2A}$ receptor antagonism, and it is unclear how they are produced. However, some NBOMe drugs, such as 25N-NBOMe, have been found to increase phosphorylation of the dopamine transporter (DAT) in the striatum similarly to methamphetamine in rodents. DAT phosphorylation is associated with dopamine reverse transport and efflux, which in turn increases extracellular dopamine levels.
Similarly to other psychedelics like DOI and 2C-T-7, tolerance has been found to gradually develop to the head-twitch response induced by 25I-NBOMe with chronic administration in rodents.

## Toxicity and harm potential

NBOMe compounds are often associated with life-threatening toxicity and death. Studies on NBOMe family of compounds demonstrated that the substance exhibit neurotoxic and cardiotoxic activity. Reports of autonomic dysfunction remains prevalent with NBOMe compounds, with most individuals experiencing sympathomimetic toxicity such as vasoconstriction, hypertension and tachycardia in addition to hallucinations. Other symptoms of toxidrome include agitation or aggression, seizure, hyperthermia, diaphoresis, hypertonia, rhabdomyolysis, and death. Researchers report that NBOMe intoxication frequently display signs of serotonin syndrome. The likelihood of seizure is higher in NBOMes compared to other psychedelics.
NBOMe and NBOHs are regularly sold as LSD in blotter papers, which have a bitter taste and different safety profiles. Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity. Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD, and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently". While most fatalities are due to the physical effects of the drug, there have also been reports of death due to self-harm and suicide under the influence of the substance.
Given limited documentation of NBOMe consumption, the long-term effects of the substance remain unknown. NBOMe compounds are not active orally, and are usually taken sublingually.$^{:3}$ When NBOMes are administered sublingually, numbness of the tongue and mouth followed by a metallic chemical taste was observed, and researchers describe this physical side effect as one of the main discriminants between NBOMe compounds and LSD.

### Neurotoxic and cardiotoxic actions

Many of the NBOMe compounds have high potency agonist activity at additional 5-HT receptors and prolonged activation of 5-HT$_{2B}$ can cause cardiac valvulopathy in high doses and chronic use. 5-HT$_{2B}$ receptors have been strongly implicated in causing drug-induced valvular heart disease. The high affinity of NBOMe compounds for adrenergic α$_1$ receptor has been reported to contribute to the stimulant-type cardiovascular effects.
In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway. 25C-NBOMe, including the other derivative 25D-NBOMe, reduced the visibility of cardiomyocytes H9c2 cells, and both substances downregulated expression level of p21 (CDC24/RAC)-activated kinase 1 (PAK1), an enzyme with documented cardiac protective effects.
Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in zebrafish, rats, and Artemia salina, a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the study also recommended further investigation of the drug's potential in damaging pregnant women and their fetus due to the substance's damaging effects to development.

### Emergency treatment

At present, there are no specific antidotes for NBOMes, and all acute intoxication is managed by symptomatic treatments, such as administration of benzodiazepines, antipsychotic drugs, and antiarrhythmic agents, such as beta blockers; some emergency interventions are intended to specifically treat rhabdomyolysis, which may lead to critical complications such as metabolic acidosis and acute kidney injury.

## Chemical structure

The 25-NB compounds are mostly N-benzylphenethylamines, though in some cases the phenyl ring of the N-benzyl group is replaced by other heterocycles such as thiophene, pyridine, furan, tetrahydrofuran, benzodioxole or naphthalene, among others.
Generally speaking, they have methoxy groups at the 2 and 5 positions of the phenyl ring, a substitution such as a halogen or alkyl group at the 4 position of the phenyl ring, and a methoxy or other substitution (e.g., hydroxyl, fluoro) at the 2 position of the N-benzyl ring. More rarely, other substitution patterns may be present (see e.g. NBOMe-mescaline, 25G-NBOMe, 2CBFly-NBOMe, 25C-NB3OMe). They differ from the 2C series by the presence of the N-benzyl moiety.
Rarely an alpha-methyl group is present making them N-benzyl amphetamines rather than N-benzyl phenethylamines, but this greatly reduces potency and activity. However in some cases where a side chain methyl group is cyclised back to the ring (e.g. in 2CBCB-NBOMe) or links the two alpha positions (e.g. in DMBMPP), this can improve selectivity for the 5-HT$_{2A}$ receptor subtype.

## List of 25-NB derivatives

This list includes notable compounds representative of most of the structural variations that have been explored in this series, but is by no means exhaustive. Many derivatives invented for scientific study into the structure-activity relationships of 5-HT$_2$ receptor agonists have never appeared as designer drugs, while conversely some derivatives that have appeared as designer drugs are structurally novel and of unknown pharmacological activity (e.g. C30-NBOMe, 5-APB-NBOMe).
| Common name | Chemical name | CAS number | R | R$_1$ | Cyc |
| 25B-NB | N-benzyl-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 155639-26-2 | 2,5-dimethoxy-4-bromo | H | phenyl |
| 25C-NB | N-benzyl-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | 1391487-65-2 | 2,5-dimethoxy-4-chloro | H | phenyl |
| 25I-NB | N-benzyl-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 919797-18-5 | 2,5-dimethoxy-4-iodo | H | phenyl |
| 25I-NMeTh | N-[(thiophen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1391499-03-8 | 2,5-dimethoxy-4-iodo | H | thiophen-2-yl |
| 25B-NMePyr | N-[(pyridin-2-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391499-21-0 | 2,5-dimethoxy-4-bromo | H | pyridin-2-yl |
| 25I-NMeFur | N-[(furan-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1391498-93-3 | 2,5-dimethoxy-4-iodo | H | furan-2-yl |
| 25I-NMeTHF | N-[(tetrahydrofuran-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | | 2,5-dimethoxy-4-iodo | H | tetrahydrofuran-2-yl |
| 25B-NBF | N-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1539266-17-5 | 2,5-dimethoxy-4-bromo | H | 2-fluorophenyl |
| 25B-NBOH | N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1335331-46-8 | 2,5-dimethoxy-4-bromo | H | 2-hydroxyphenyl |
| 25B-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1026511-90-9 | 2,5-dimethoxy-4-bromo | H | 2-methoxyphenyl |
| 25B-NB23DM | N-(2,3-dimethoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391493-68-7 | 2,5-dimethoxy-4-bromo | H | 2,3-dimethoxyphenyl |
| 25B-NB25DM | N-(2,5-dimethoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | | 2,5-dimethoxy-4-bromo | H | 2,5-dimethoxyphenyl |
| 25B-NMe7BF | N-[(benzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391492-46-8 | 2,5-dimethoxy-4-bromo | H | benzofuran-7-yl |
| 25B-NMe7DHBF | N-[(2,3-dihydrobenzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391492-40-2 | 2,5-dimethoxy-4-bromo | H | 2,3-dihydrobenzofuran-7-yl |
| 25B-NMe7BT | N-[(benzothiophen-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391492-59-3 | 2,5-dimethoxy-4-bromo | H | benzothiophen-7-yl |
| 25B-NMe7Box | N-[(benzoxazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391498-73-9 | 2,5-dimethoxy-4-bromo | H | benzoxazol-7-yl |
| 25B-NMe7Ind | N-[(indol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391498-28-4 | 2,5-dimethoxy-4-bromo | H | indol-7-yl |
| 25B-NMe7Indz | N-[(indazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391498-43-3 | 2,5-dimethoxy-4-bromo | H | indazol-7-yl |
| 25B-NMe7Bim | N-[(benzimidazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1391498-62-6 | 2,5-dimethoxy-4-bromo | H | benzimidazol-7-yl |
| FECIMBI-36 | N-[(2-fluoroethoxy)benzyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | | 2,5-dimethoxy-4-bromo | H | 2-(2-fluoroethoxy)phenyl |
| DOB-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane | | 2,5-dimethoxy-4-bromo | methyl | 2-methoxyphenyl |
| 25C-NB3OMe | N-(3-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | 1566571-34-3 | 2,5-dimethoxy-4-chloro | H | 3-methoxyphenyl |
| 25C-NB4OMe | N-(4-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | 1566571-35-4 | 2,5-dimethoxy-4-chloro | H | 4-methoxyphenyl |
| C30-NBOMe | N-(3,4,5-trimethoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | 1445574-98-0 | 2,5-dimethoxy-4-chloro | H | 3,4,5-trimethoxyphenyl |
| 25C-NBF | N-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | 1539266-21-1 | 2,5-dimethoxy-4-chloro | H | 2-fluorophenyl |
| 25C-NBCl | N-(2-chlorobenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | | 2,5-dimethoxy-4-chloro | H | 2-chlorophenyl |
| 25C-NBOH | N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | 1391488-16-6 | 2,5-dimethoxy-4-chloro | H | 2-hydroxyphenyl |
| 25C-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | 1227608-02-7 | 2,5-dimethoxy-4-chloro | H | 2-methoxyphenyl |
| 25C-NBOEt | N-(2-ethoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | | 2,5-dimethoxy-4-chloro | H | 2-ethoxyphenyl |
| 25C-NBOiPr | N-(2-isopropoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | | 2,5-dimethoxy-4-chloro | H | 2-isopropoxyphenyl |
| 25F-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-fluorophenyl)-2-aminoethane | 1373917-84-0 | 2,5-dimethoxy-4-fluoro | H | 2-methoxyphenyl |
| 25CN-NBOH | N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-cyanophenyl)-2-aminoethane | 1539266-32-4 | 2,5-dimethoxy-4-cyano | H | 2-hydroxyphenyl |
| 25CN-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-cyanophenyl)-2-aminoethane | 1354632-16-8 | 2,5-dimethoxy-4-cyano | H | 2-methoxyphenyl |
| 25D-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane | 1354632-02-2 | 2,5-dimethoxy-4-methyl | H | 2-methoxyphenyl |
| 25D-NBOH | N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane | 1391488-44-0 | 2,5-dimethoxy-4-methyl | H | 2-hydroxyphenyl |
| 25E-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-ethylphenyl)-2-aminoethane | 1354632-14-6 | 2,5-dimethoxy-4-ethyl | H | 2-methoxyphenyl |
| 25E-NBOH | N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-ethylphenyl)-2-aminoethane | 1391489-79-4 | 2,5-dimethoxy-4-ethyl | H | 2-hydroxyphenyl |
| 25G-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-3,4-dimethylphenyl)-2-aminoethane | 1354632-65-7 | 2,5-dimethoxy-3,4-dimethyl | H | 2-methoxyphenyl |
| 25H-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxyphenyl)-2-aminoethane | 1566571-52-5 | 2,5-dimethoxy | H | 2-methoxyphenyl |
| 25I-NB34MD | N-(3,4-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1391497-81-6 | 2,5-dimethoxy-4-iodo | H | 3,4-methylenedioxyphenyl |
| 25I-NB3OMe | N-(3-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1566571-40-1 | 2,5-dimethoxy-4-iodo | H | 3-methoxyphenyl |
| 25I-NB4OMe | N-(4-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1566571-41-2 | 2,5-dimethoxy-4-iodo | H | 4-methoxyphenyl |
| 25I-NBF | N-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 919797-21-0 | 2,5-dimethoxy-4-iodo | H | 2-fluorophenyl |
| 25I-NBBr | N-(2-bromobenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1648649-98-2 | 2,5-dimethoxy-4-iodo | H | 2-bromophenyl |
| 25I-NBTFM | N-[2-(trifluoromethyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | | 2,5-dimethoxy-4-iodo | H | 2-(trifluoromethyl)phenyl |
| 25I-NBMD | N-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 919797-25-4 | 2,5-dimethoxy-4-iodo | H | 2,3-methylenedioxyphenyl |
| 25B-NBMD | N-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane | 1354632-19-1 | 2,5-dimethoxy-4-bromo | H | 2,3-methylenedioxyphenyl |
| 25C-NBMD | N-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane | 1373879-26-5 | 2,5-dimethoxy-4-chloro | H | 2,3-methylenedioxyphenyl |
| 25D-NBMD | N-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane | 1391488-97-3 | 2,5-dimethoxy-4-methyl | H | 2,3-methylenedioxyphenyl |
| 25I-NBOH | N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 919797-20-9 | 2,5-dimethoxy-4-iodo | H | 2-hydroxyphenyl |
| 25I-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 919797-19-6 | 2,5-dimethoxy-4-iodo | H | 2-methoxyphenyl |
| DOI-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane | | 2,5-dimethoxy-4-iodo | methyl | 2-methoxyphenyl |
| 25I-NBMeOH | N-[2-(hydroxymethyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1391494-71-5 | 2,5-dimethoxy-4-iodo | H | 2-(hydroxymethyl)phenyl |
| 25I-NBAm | N-[2-(carbamoyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1391494-85-1 | 2,5-dimethoxy-4-iodo | H | 2-(carbamoyl)phenyl |
| 25I-NMe7DHBF | N-[(2,3-dihydrobenzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | | 2,5-dimethoxy-4-iodo | H | 2,3-dihydrobenzofuran-7-yl |
| 25I-N2Nap1OH | N-[(1-hydroxynaphthalen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | | 2,5-dimethoxy-4-iodo | H | 1-hydroxynaphthalen-2-yl |
| 25I-N3MT2M | N-[(3-methoxythiophen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1354632-66-8 | 2,5-dimethoxy-4-iodo | H | 3-methoxythiophen-2-yl |
| 25I-N4MT3M | N-[(4-methoxythiophen-3-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane | 1354632-73-7 | 2,5-dimethoxy-4-iodo | H | 4-methoxythiophen-3-yl |
| 25iP-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-isopropylphenyl)-2-aminoethane | 1391487-83-4 | 2,5-dimethoxy-4-isopropyl | H | 2-methoxyphenyl |
| 25N-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane | 1354632-03-3 | 2,5-dimethoxy-4-nitro | H | 2-methoxyphenyl |
| 25N-NBOEt | N-(2-ethoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane | | 2,5-dimethoxy-4-nitro | H | 2-ethoxyphenyl |
| 25N-NB-2-OH-3-Me | N-(2-hydroxy-3-methylbenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane | | 2,5-dimethoxy-4-nitro | H | 2-hydroxy-3-methylphenyl |
| 25N-NBOCF2H | N-(2-difluoromethoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane | | 2,5-dimethoxy-4-nitro | H | 2-difluoromethoxyphenyl |
| 25N-NBPh | N-[(2-phenyl)benzyl]-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane | | 2,5-dimethoxy-4-nitro | H | o-biphenyl |
| 25N-N1-Nap | N-[(naphthalen-1-yl)methyl]-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane | | 2,5-dimethoxy-4-nitro | H | 1-naphthyl |
| 25P-NBOMe | N-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-propylphenyl)-2-aminoethane | 1391489-07-8 | 2,5-dimethoxy-4-propyl | H | 2-methoxyphenyl |
| 25P-NBOH | N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-propylphenyl)-2-aminoethane | 1391490-34-8 | 2,5-dimethoxy-4-propyl | H | 2-hydroxyphenyl |
| 25TFM-NBOMe | N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(trifluoromethyl)phenyl]-2-aminoethane | 1027161-33-6 | 2,5-dimethoxy-4-(trifluoromethyl) | H | 2-methoxyphenyl |
| 25O-NBcP | N-(2-cyclopropylbenzyl)-1-(2,4,5-trimethoxyphenyl)-2-aminoethane | | 2,4,5-trimethoxy | H | 2-cyclopropylphenyl |
| 25T-NBOMe | N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(methylthio)phenyl]-2-aminoethane | 1539266-47-1 | 2,5-dimethoxy-4-(methylthio) | H | 2-methoxyphenyl |
| 25T2-NBOMe | N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(ethylthio)phenyl]-2-aminoethane | 1539266-51-7 | 2,5-dimethoxy-4-(ethylthio) | H | 2-methoxyphenyl |
| 25T4-NBOMe | N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(isopropylthio)phenyl]-2-aminoethane | 1354632-17-9 | 2,5-dimethoxy-4-(isopropylthio) | H | 2-methoxyphenyl |
| 25T7-NBOMe | N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(propylthio)phenyl]-2-aminoethane | 1539266-55-1 | 2,5-dimethoxy-4-(propylthio) | H | 2-methoxyphenyl |
| 25T7-NBOH | N-(2-hydroxybenzyl)-1-[2,5-dimethoxy-4-(propylthio)phenyl]-2-aminoethane | 1354632-41-9 | 2,5-dimethoxy-4-(propylthio) | H | 2-hydroxyphenyl |
| 25AM-NBOMe | N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-pentylphenyl]-2-aminoethane | | 2,5-dimethoxy-4-(n-pentyl) | H | 2-methoxyphenyl |
| NBOMe-mescaline | N-(2-methoxybenzyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethane | 1354632-01-1 | 3,4,5-trimethoxy | H | 2-methoxyphenyl |
| NBOMe-escaline | N-(2-methoxybenzyl)-1-(3,5-dimethoxy-4-ethoxyphenyl)-2-aminoethane | | 3,5-dimethoxy-4-ethoxy | H | 2-methoxyphenyl |
| NBOMe-thiobuscaline | N-(2-methoxybenzyl)-1-(3,5-dimethoxy-4-butylthiophenyl)-2-aminoethane | | 3,5-dimethoxy-4-(n-butylthio) | H | 2-methoxyphenyl |
| MDPEA-NBOMe | N-(2-methoxybenzyl)-1-(3,4-methylenedioxyphenyl)-2-aminoethane | | 3,4-methylenedioxy | H | 2-methoxyphenyl |
| 2C2-NBOMe | N-(2-methoxybenzyl)-1-(2-methoxy-4,5-methylenedioxyphenyl)-2-aminoethane | | 2-methoxy-4,5-methylenedioxy | H | 2-methoxyphenyl |
| MDBZ | N-benzyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane | 65033-29-6 | 3,4-methylenedioxy | methyl | phenyl |
| Clobenzorex | N-(2-chlorobenzyl)-1-phenyl-2-aminopropane | 13364-32-4 | H | methyl | 2-chlorophenyl |
| 4-EA-NBOMe | N-(2-methoxybenzyl)-1-(4-ethylphenyl)-2-aminopropane | | 4-ethyl | methyl | 2-methoxyphenyl |
| 5-APB-NBOMe | N-(2-methoxybenzyl)-1-(benzofuran-5-yl)-2-aminopropane | | benzofuran-5-yl instead of phenyl | methyl | 2-methoxyphenyl |

## Related compounds

Similar compounds with related structures are also known including;
| Common name | Chemical name | CAS number |
| 25B-N1POMe | N-[1-(2-methoxyphenyl)ethyl]-2,5-dimethoxy-4-bromophenethylamine | 1335331-49-1 (R) 1335331-51-5 (S) |
| 2C-B-AN | 2-phenyl-2-[2-(2,5-dimethoxy-4-bromophenyl)ethylamino]acetonitrile | |
| 25B-N(BOMe)2 | 2-(4-Bromo-2,5-dimethoxyphenyl)-N,N-bis(2-methoxybenzyl)ethan-1-amine | |
| 25CN-N3DHBF | 4-(2-[(2,3-dihydro-1-benzofuran-3-yl)amino]ethyl)-2,5-dimethoxybenzonitrile | |
| 2CBCB-NBOMe | N-[(3-bromo-2,5-dimethoxy-bicyclo[4,2,0]octa-1,3,5-trien-7-yl)methyl]-1-(2-methoxyphenyl)methanamine | 1354634-09-5 |
| 2CBFly-NBOMe | N-(2-methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane | 1335331-42-4 |
| 2C-B-DRAGONFLY-NBOH | N-(2-hydroxybenzyl)-1-(8-bromobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane | 1335331-45-7 |
| 2C-B-FLY-NB2EtO5Cl | N-(2-ethoxy-5-chlorobenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane | |
| DMBMPP | (S,S)-2-(2,5-dimethoxy-4-bromobenzyl)-6-(2-methoxyphenyl)piperidine | 1391499-52-7 |
| 25B-NAcPip | 2-{[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino}-1-(piperidin-1-yl)ethanone | |
| ZDCM-04 | 1,3-dimethyl-7-{2-[1-(2,5-dimethoxy-4-chlorophenyl)propan-2-ylamino]ethyl}purine-2,6-dione | |
| RH-34 | 3-[2-(2-methoxybenzylamino)ethyl]-1H-quinazoline-2,4-dione | 1028307-48-3 |
| 5-MeO-T-NBOMe | N-(2-methoxybenzyl)-5-methoxytryptamine | 1335331-37-7 |
| 5MT-NB3OMe | N-(3-methoxybenzyl)-5-methoxytryptamine | 1648553-42-7 |

## Legality
### United Kingdom

A large number of substances in the 25-NB class are Class A drugs in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971 or are otherwise covered by the Psychoactive Substances Act 2016.